Claims

1. A compound having the general formula I:



Formula I

wherein

n is 0 or 1;

X^1 and X^2 are independently, at each occurrence, CR^5 or N;

Y is C_1-C_6 alkylene, wherein alkylene is optionally substituted with one to two C_1-C_3 alkyl groups;

R^1 is selected from the group consisting of hydrogen, halogen, C_1-C_6 alkoxy, $-NH_2$, $-NHR^6$, $-NR^7R^8$ and $-NH-(R^9)_n-R^{10}$, n being 0 or 1;

R^2 is selected from the group consisting of hydrogen, C_1-C_6 alkyl,$-NH_2$, $-NHR^6$, $-NR^7R^8$ and $-NH-(R^9)_n-R^{10}$ group, n being 0 or 1;

with the proviso that R^1 and R^2 are not hydrogen at the same time,

R^3 is selected from the group consisting of OR^{11}, $-NR^7R^8$, C_1-C_6 alkoxy, C_1-C_6 alkyl, C_3-C_{10}cycloalkyl, C_1-C_3 haloalkyl,$-C(O)NHR^{11}$, and heteroaryl group, wherein each of said cycloalkyl, and heteroaryl is optionally and independently substituted with one to four R^a groups;

R^4 is selected from the group consisting of $-N(R^{12})(V)_pR^{13}$, $-NH(V)_p-OR^{14}$, $-NHC(O)R^{15}$, and groups of formula Ia shown below,



Formula Ia

wherein,

p is 0 or 1,

V is C_1-C_6 alkylene, wherein alkylene is optionally substituted with one to three C_1-C_3 alkyl, C_3-C_6 cycloalkyl or phenyl groups, or wherein a carbon atom of said alkylene forms part of a C_3-C_6 cycloalkyl group;

R^5 is selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 alkoxy group;

R^6 is selected from the group consisting of C_1-C_6 alkyl, C_3-C_{10}cycloalkyl, C_1-C_6 haloalkyl, aryl, heteroaryl and heterocyclyl group, wherein each of said alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups;

R^7 and R^8 are independently, at each occurrence, C_1-C_6 alkyl or heterocyclyl; or
R^7 and R^8 are connected to each other to make a four, five or six membered heterocyclyl or heteroaryl group, wherein each of said heterocyclyl and heteroaryl is optionally and independently substituted with one to four R^a groups;

R^9 is C_1-C_4 alkylene, wherein said alkylene is optionally substituted with one to three C_1-C_3 alkyl groups;

R^{10} is selected from the group consisting of hydroxyl, -OR^{11}, -CN, -$C(O)OR^{18}$, -$C(O)NH_2$, -$C(NH)NH_2$, heteroaryl and heterocyclyl group wherein each of said heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups;

R^{11} is independently, at each occurrence, selected from the group consisting of aryl, heteroaryl and heterocyclyl group wherein each of said aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups;

R^{12} is selected from the group consisting of hydrogen, C_1-C_6 alkyl, C_1-C_4 alkyl-hydroxyl and C_1-C_4 alkyl-alkoxy;

R^{13} is selected from the group consisting of hydrogen, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, C_1-C_4 alkyl-hydroxyl, -OH, -$C(O)NH_2$, -$C(O)OR^{18}$, -CN, C_1-C_3 haloalkyl and heterocyclyl, and groups of formula Ib shown below,



Formula Ib

wherein,

n is 0 or 1;

A^1 is -O-, -CH_2O-, -OCH_2-, -S-, -SO_2-, -SO_2NH-, -C(O)-, -C(O)NH-, -$C(O)N(R^7)$-, -CH(OH)-, -$CH(OR^7)$-, -NH-, -$N(CH_3)$- or -$N(CH_2COOR^7)$-;

A^2 is –O- or NH-;

B is selected from the group consisting of aryl, heteroaryl and heterocyclyl group wherein each of said aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups;

with the proviso that R^{12} and R^{13} are not hydrogen at the same time;

with the proviso that when R^{12} is hydrogen, R^{13} is not C_1 alkyl;

R^{14} is selected from the group consisting of hydrogen, C_1-C_6 alkyl and aryl, wherein each of said alkyl and aryl is optionally and independently substituted with one to four halogen or C_1-C_3 haloalkoxy groups;

R^{15} is aryl, wherein aryl is optionally substituted with one to four halogen groups;

R^{16} is selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl and hydroxyl ;

R^{17} is selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl, -C(O)R^{11}, -C(O)NHR^{11}, -OR^{11} and aryl , wherein each of said alkyl and aryl is optionally and independently substituted with one to four R^a groups;

R^{18} is hydrogen or C_1-C_6 alkyl;

R^{19} is selected from the group consisting of hydrogen, -OR^{22} and -CH_2OR^{22};

R^{20} is selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy, –C(O)R^a and C_1-C_6 haloalkoxy;

R^{21} is selected from the group consisting of hydrogen, halogen and C_1-C_6 alkyl group;

R^{22} is selected from the group consisting of C_1-C_6 haloalkyl, aryl, and heteroaryl, wherein each of said haloalkyl, aryl and heteroaryl is optionally and independently substituted with one to four R^a groups;

R^a is independently, at each occurrence, selected from the group consisting of hydrogen, halogen, C_1-C_3 alkyl, C_3-C_{10} cycloalkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_6 haloalkoxy, hydroxyl, C_1-C_3 alkylhydroxyl, –CH_2OR^c, –OCH_2R^c, -OR^c, -CN, NO_2, -N$R^b$$R^c$, -C(O)N$R^b$$R^c$, -C(NH)$NH_2$, -C(O)$R^c$, -C(O)O$R^c$, sulfonyl, sulfoxide, heterocyclyl, heteroaryl and aryl, wherein each of said alkyl, haloalkyl, haloalkoxy, alkoxy, cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four C_1-C_3 alkyl, C_1-C_4 alkoxy, halogen, C_1-C_3 haloalkyl, -CN, -C(O)NH_2, -COOH, -CO_2Et and heteroaryl;

R^b is independently, at each occurrence, selected from the group consisting of hydrogen, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_1-C_6 alkyl-O-alkyl, C_2-C_{10} alkenyl, C_1-C_4 alkoxy, C_1-C_3 alkylhydroxyl, C_3-C_{10} cycloalkenyl, C_2-C_{10} alkynyl, C_1-C_6 haloalkyl, aryl, heteroaryl, and heterocyclyl wherein each of said alkyl, cycloalkyl, alkyl-O-alkyl, alkenyl, alkoxy, cycloalkenyl, alkynyl, haloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four C_1-C_3 alkyl, C_1-C_4 alkoxy, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, hydroxyl, -C(O)NH_2, -COOH, -COOMe, -COOEt, -CN, -NO_2, -NH_2;

R^c is independently, at each occurrence, selected from the group consisting of hydrogen, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_1-C_6 alkyl-O-alkyl, C_2-C_{10} alkenyl, C_1-C_4 alkoxy, C_1-C_3 alkylhydroxyl, C_3-C_{10} cycloalkenyl, C_2-C_{10} alkynyl, C_1-C_6 haloalkyl, heteroaryl, and heterocyclyl wherein each of said alkyl, cycloalkyl, alkyl-O-alkyl, alkenyl, alkoxy, cycloalkenyl, alkynyl, haloalkyl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four C_1-C_3 alkyl, C_1-C_4 alkoxy, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, hydroxyl, -C(O)NH_2, -COOH, -COOMe, -COOEt, -CN, -NO_2, -NH_2; or

R^b and R^c are connected to each other to make a four, five or six membered saturated or unsaturated cyclic or heterocyclic ring;

and pharmaceutically acceptable salts thereof.

2. The compound according to claim 1 having the general formula II:



Formula II

wherein
n is 0 or 1;
X^1 is CR^5 or N;

Y is C_1-C_6 alkylene, wherein alkylene is optionally substituted with one to two C_1-C_3 alkyl groups;

R^5 is selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 alkoxy group;

R^{23} is selected from the group consisting of C_1-C_6 alkyl, C_1-C_3 haloalkyl and heteroaryl group, wherein the heteroaryl group is optionally and independently substituted with one to four R^a groups;

R^{24} is selected from the group consisting of hydrogen, C_3-C_{10}cycloalkyl, aryl, heteroaryl and heterocyclyl group, wherein each of said cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups;

R^{25} is selected from the group consisting of $-(V)_pR^{26}$ and $-(V)_p$-OR^{14} ;

wherein,
p is 0 or 1,
V is C_1-C_6 alkylene, wherein alkylene is optionally substituted with one to three C_1-C_3 alkyl or phenyl groups, or wherein a carbon atom of said alkylene forms part of a C_3-C_6 cycloalkyl group;

R^{14} is selected from the group consisting of hydrogen, C_1-C_6 alkyl and aryl, wherein each of said alkyl and aryl is optionally and independently substituted with one to four halogen or C_1-C_3 haloalkoxy groups;

R^{26} is selected from the group consisting of hydrogen, C_1-C_6 alkyl, -CN and C_1-C_3 haloalkyl, and groups of formula IIa shown below,



Formula IIa

wherein,

A^2 is -O- or NH-;

A^3 is -O-, $-CH_2O-$, $-OCH_2-$, or –NH-;

B is selected from the group consisting of aryl, heteroaryl and heterocyclyl group wherein each of said aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups;

R^{19} is selected from the group consisting of hydrogen, $-OR^{22}$ and $-CH_2OR^{22}$;

R^{20} is selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy and C_1-C_6 haloalkoxy;

R^{21} is selected from the group consisting of hydrogen, halogen and C_1-C_6 alkyl;

R^{22} is selected from the group consisting of aryl, and heteroaryl, wherein each of said aryl and heteroaryl is optionally and independently substituted with one to four R^a groups;

R^a is independently, at each occurrence, selected from the group consisting of hydrogen, halogen, C_1-C_3 alkyl, C_3-C_{10} cycloalkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_6 haloalkoxy, hydroxyl, C_1-C_3 alkylhydroxyl, $–CH_2OR^c$, $–OCH_2R^c$, $-OR^c$, -CN, NO_2, $-NR^bR^c$, $-C(O)NR^bR^c$, $-C(NH)NH_2$, $-C(O)R^c$, $-C(O)OR^c$, sulfonyl, sulfoxide, heterocyclyl, heteroaryl and aryl, wherein each of said alkyl, haloalkyl, haloalkoxy, alkoxy, cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four C_1-C_3 alkyl, C_1-C_4 alkoxy, halogen, C_1-C_3 haloalkyl, -CN, $-C(O)NH_2$, -COOH, $-CO_2Et$ and heteroaryl;

R^b and R^c are independently, at each occurence, selected from the group consisting of hydrogen, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_1-C_6 alkyl-O-alkyl, C_2-C_{10} alkenyl, C_1-C_4 alkoxy, C_1-C_3 alkylhydroxyl, C_3-C_{10} cycloalkenyl, C_2-C_{10} alkynyl, C_1-C_6 haloalkyl, aryl, heteroaryl, and heterocyclyl wherein each of said alkyl, alkyl-O-alkyl, alkenyl, alkoxy, cycloalkenyl, alkynyl, haloalkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four C_1-C_3 alkyl, C_1-C_4 alkoxy, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, hydroxyl, -C(O)NH_2, -COOH, -COOMe, -COOEt, -CN, -NO_2, -NH_2; or

R^b and R^c are connected to each other to make a four, five or six membered saturated or unsaturated cyclic or heterocyclic ring;

and pharmaceutically acceptable salts thereof.

3. The compound according to claim 1 having the general formula III:



Formula III

wherein

n is 0 or 1;

X^1 is CR^5 or N;

Y is C_1-C_6 alkylene, wherein alkylene is optionally substituted with one to two C_1-C_3 alkyl groups;

R^5 is selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl, C_1-C_6 haloalkyl and C_1-C_6 alkoxy group;

R^{23} is selected from the group consisting of C_1-C_6 alkyl, aryl and heteroaryl group, wherein each of said aryl and heteroaryl is optionally and independently substituted with one to four R^a groups;

R^{27} is selected from the group consisting of hydrogen, $-R^6$, and $-R^9-R^{10}$;
wherein,

R^6 is selected from the group consisting of C_1-C_6 alkyl, C_3-C_{10}cycloalkyl, C_1-C_6 haloalkyl, heteroaryl and heterocyclyl group, wherein said alkyl, cycloalkyl, haloalkyl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups;

R^9 is C_1-C_4 alkylene, wherein said alkylene is optionally substituted with one to three C_1-C_3 alkyl groups;

R^{10} is selected from the group consisting of hydroxyl, $-OR^{11}$, $-C(O)OR^{18}$, $-C(O)NH_2$, heteroaryl and heterocyclyl group wherein each of said heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups;

R^{11} is independently, at each occurrence selected from the group consisting of aryl, heteroaryl and heterocyclyl group wherein said aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups;

R^{18} is hydrogen or C_1-C_6 alkyl;

R^{28} is selected from the group consisting of $-(V)_pR^{29}$ and $-(V)_p-OR^{14}$ group;

wherein,
p is 0 or 1,
V is C_1-C_6 alkylene, wherein alkylene is optionally substituted with one to three C_1-C_3 alkyl or phenyl groups;

R^{14} is selected from the group consisting of hydrogen, C_1-C_6 alkyl and aryl, wherein each of said alkyl and aryl is optionally and independently substituted with one to four halogen or C_1-C_3 haloalkoxy groups;

R^{29} is selected from the group consisting of hydrogen and C_1-C_3 haloalkyl, and groups of formula IIIa shown below,



Formula IIIa

wherein,

A^2 is -O- or NH-;

A^3 is -O-, $-CH_2O-$, $-OCH_2-$, or –NH-;

B is selected from the group consisting of aryl, heteroaryl and heterocyclyl group wherein each of said aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups;

R^{19} is selected from the group consisting of hydrogen, $-OR^{22}$ and $-CH_2OR^{22}$;

R^{20} is selected from the group consisting of hydrogen, halogen, C_1-C_6 alkyl, C_1-C_6 alkoxy and C_1-C_6 haloalkoxy;

R^{21} is selected from the group consisting of hydrogen, halogen and C_1-C_6 alkyl;

R^{22} is selected from the group consisting of aryl, and heteroaryl, wherein said aryl and heteroaryl is optionally and independently substituted with one to four R^a groups;

R^a is independently, at each occurrence, selected from the group consisting of hydrogen, halogen, C_1-C_3 alkyl, C_3-C_{10} cycloalkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_6 haloalkoxy, hydroxyl, C_1-C_3 alkylhydroxyl, $–CH_2OR^c$, $–OCH_2R^c$, $-OR^c$, -CN, NO_2, $-NR^bR^c$, $-C(O)NR^bR^c$, $-C(NH)NH_2$, $-C(O)R^c$, $-C(O)OR^c$, sulfonyl, sulfoxide, heterocyclyl, heteroaryl and aryl,

wherein each of said alkyl, haloalkyl, haloalkoxy, alkoxy, cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four C_1-C_3 alkyl, C_1-C_4 alkoxy, halogen, C_1-C_3 haloalkyl, -CN, -C(O)NH_2, -COOH, -CO_2Et and heteroaryl;

R^b and R^c are independently, at each occurrence, selected from the group consisting of hydrogen, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_1-C_6 alkyl-O-alkyl, C_2-C_{10} alkenyl, C_1-C_4 alkoxy, C_1-C_3 alkylhydroxyl, C_3-C_{10} cycloalkenyl, C_2-C_{10} alkynyl, C_1-C_6 haloalkyl, aryl, heteroaryl, and heterocyclyl wherein each of said alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four C_1-C_3 alkyl, C_1-C_4 alkoxy, halogen, C_1-C_6 haloalkyl, C_1-C_6 haloalkoxy, hydroxyl, -C(O)NH_2,
-COOH, -COOMe , -COOEt, -CN, -NO_2, -NH_2; or
R^b and R^c are connected to each other to make a four, five or six membered saturated or unsaturated cyclic or heterocyclic ring;
and pharmaceutically acceptable salts thereof.

4. The compound according to any of claims 1-3, having one of the formulae 1- 556, as shown in table below

No.	Structure
1	
2	
3	
4	

5	
6	
7	
8	
9	
10	
11	
12	
13	

14	
15	
16	
17	
18	
19	
20	
21	
22	

23	
24	
25	
26	
27	
28	
29	
30	
31	
32	

33	
34	
35	
36	
37	
38	
39	
40	
41	

42	
43	
44	
45	
46	
47	
48	
49	
50	

51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	

62	
63	
64	
65	
66	
67	
68	
69	
70	
71	

72	
73	
74	
75	
76	
77	
78	
79	
80	

81	
82	
83	
84	
85	
86	
87	
88	



89	
90	
91	
92	
93	
94	
95	
96	

97	
98	
99	
100	
101	
102	
103	

104	
105	
106	
107	
108	
109	
110	
111	

112	
113	
114	
115	
116	
117	
118	
119	

120	
121	
122	
123	
124	
125	
126	
127	

128	
129	
130	
131	
132	
133	
134	
135	

136	
137	
138	
139	
140	
141	
142	
143	

144	
145	
146	
147	
148	
149	
150	
151	

152	
153	
154	
155	
156	
157	
158	
159	

160	
161	
162	
163	
164	
165	
166	
167	

168	
169	
170	
171	
172	
173	
174	
175	

176	
177	
178	
179	
180	
181	
182	
183	

184	
185	
186	
187	
188	
189	
190	
191	

192	
193	
194	
195	
196	
197	
198	
199	

200	
201	
202	
203	
204	
205	
206	
207	

208	
209	
210	
211	
212	
213	
214	
215	

216	
217	
218	
219	
220	
221	
222	
223	

224	
225	
226	
227	
228	
229	
230	
231	

232	
233	
234	
235	
236	
237	
238	
239	

240	
241	
242	
243	
244	
245	
246	
247	

248	
249	
250	
251	
252	
253	
254	
255	

256	
257	
258	
259	
260	
261	
262	
263	

264	
265	
266	
267	
268	
269	
270	
271	

272	
273	
274	
275	
276	
277	
278	
279	

280	
281	
282	
283	
284	
285	
286	
287	

288	
289	
290	
291	
292	
293	
294	
295	

296	
297	
298	
299	
300	
301	
302	
303	

304	
305	
306	
307	
308	
309	
310	
311	

312	
313	
314	
315	
316	
317	
318	
319	

320	
321	
322	
323	
324	
325	
326	
327	

328	
329	
330	
331	
332	
333	
334	
335	

336	
337	
338	
339	
340	
341	
342	
343	

344	
345	
346	
347	
348	
349	
350	
351	

352	
353	
354	
355	
356	
357	
358	
359	

360	
361	
362	
363	
364	
365	
366	
367	

368	
369	
370	
371	
372	
373	
374	
375	

376	
377	
378	
379	
380	
381	
382	
383	

384	
385	
386	
387	
388	
389	
390	
391	

392	
393	
394	
395	
396	
397	
398	
399	

400	
401	
402	
403	
404	
405	
406	
407	

408	
409	
410	
411	
412	
413	
414	
415	

416	
417	
418	
419	
420	
421	
422	
423	

424	
425	
426	
427	
428	
429	
430	
431	

432	
433	
434	
435	
436	
437	
438	

439	
440	
441	
442	
443	
444	
445	
446	

447	
448	
449	
450	
451	
452	
453	

454	
455	
456	
457	
458	
459	
460	
461	

462	
463	
464	
465	
466	
467	
468	
469	

470	
471	
472	
473	
474	
475	
476	
477	

478	
479	
480	
481	
482	
483	
484	
485	

486	
487	
488	
489	
490	
491	
492	
493	

494	
495	
496	
497	
498	
499	
500	
501	

502	
503	
504	
505	
506	
507	
508	
509	

510	
511	
512	
513	
514	
515	
516	
517	

518	
519	
520	
521	
522	
523	
524	
525	

526	
527	
528	
529	
530	
531	
532	

533	
534	
535	
536	
537	
538	
539	

540	
541	
542	
543	
544	
545	
546	

547	
548	
549	
550	
551	
552	
553	

554	
555	
556	

; or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1, wherein R^4 is $–N(R^{12})(V)_pR^{13}$, R^{12} is H, V is C_1-alkylene, p is 1, R^{13} is



and B is heteroaryl which is optionally substituted with one to four R^a groups**.**

6. The compound according to any of claims 1 or 5 wherein R^1 is $–NH_2$ or $–NHR^6$, R^6 is heteroaryl or heterocyclyl wherein each of said heteroaryl and heterocyclyl is optionally and independently substituted with one to four R^a groups.

7. The compound according to any of claims 1- 6 or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease associated with the 5LOX-pathway and/or the prostaglandin E synthase (PGES) pathway, said disease being selected from inflammatory diseases, e.g. asthma, atherosclerosis, pain, or COPD, cancer, stroke and Alzheimer's disease.

8. The compound according to any of claims 1- 7, wherein said compound has an inhibitory activity on an enzyme involved in an inflammatory pathway or several inflammatory pathways, e.g. the arachidonate 5-lipoxygenese pathway and/or the prostaglandin E synthase pathway, preferably on arachidonate 5-lipoxygenase (5-lipoxygenase, 5-LO, 5-LOX, Alox5), at a concentration of said compound between 0.001-50μM, particularly preferably having an IC_{50} on arachidonate 5-lipoxygenase of less than 1μM and/or having an EC_{50} of less than 10μM on the production of leukotriene B4 (LTB4) in rat basophilic leucocyte cells (RBL) and/or rat whole blood (RWB), and/or having a 40-70 % inhibitory activity, preferably a>70 % inhibitory activity on the production of prostaglandin E2 in HeLaS3 cells, stimulated with TNF-α, at a concentration of 10μM of said compound.

9. A composition comprising a compound or a pharmaceutically acceptable salt thereof, as defined in any of claims 1- 6, and a pharmaceutically acceptable carrier.

10. The composition according to claim 9, for use in the treatment of a disease associated with the 5LOX-pathway and/or the prostaglandin E synthase (PGES) pathway, said disease being selected from inflammatory diseases, e.g. asthma, atherosclerosis, pain, or COPD, cancer, stroke and Alzheimer's disease.

11. The compound or composition for use according to any of claims 7 or 10 wherein said inflammatory disease is one or several of asthma, allergic rhinitis, dermatitis, chronic obstructive pulmonary disease (COPD), inflammation post infection, arthritis, atherosclerosis, allergies, such as hay fever, autoimmune diseases, such as lupus erythematosus, inflammatory bowel diseases, such as Crohn's disease, celiac disease, acne, or pain, e.g. inflammatory and/or neuropathic pain.

12. The compound or composition for use according to any of claims 7 and 10-11 wherein a treatment to a patient in need thereof, suffering from an inflammatory disease, and/or of cancer, and/or of stroke, and/or of Alzheimer's disease comprises administering a suitable amount of a compound as defined in any of claims 1-6, or of a composition as defined in

claim 9.

13. Use of a suitable amount of a compound as defined in any of claims 1-6 or a composition as defined in claim 9 in the manufacture of a medicament for the treatment of a disease associated with the 5-LOX-pathway and/or the prostaglandin E synthase (PGES) pathway, wherein said disease being selected from inflammatory diseases, cancer and Alzheimer's disease.

14. The use according to claim 13 , wherein said inflammatory disease is selected from asthma, allergic rhinitis, dermatitis, chronic obstructive pulmonary disease (COPD), inflammation post infection, arthritis, atherosclerosis, allergies, such as hay fever, autoimmune diseases, such as lupus erythematosus, inflammatory bowel diseases, such as Crohn's disease, celiac disease, acne, and pain, e.g. inflammatory and/or neuropathic pain.

15. The compound or composition for use according to claim 12 or the use according to any of claims 13-14, wherein said suitable amount is an amount in the range of 0.01mg/kg body weight to 1g/kg body weight of said patient.